

RESEARCH ARTICLE

Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort

Niyatee Samudra¹ | D. Luke Fischer¹ | Steven Lenio¹ | Argentina Lario Lago¹ | Peter A. Ljubenkov¹ | Julio C. Rojas¹ | William W. Seeley¹ | Salvatore Spina¹ | Adam M. Staffaroni¹ | Jonathan Tablante¹ | Fattin Wekselman¹ | Jennifer Lamoureux² | Luis Concha-Marambio² | Lea T. Grinberg^{1,3} | Adam L. Boxer¹ | Lawren VandeVrede¹

¹Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA

²Amprion Inc., San Diego, California, USA

³Department of Pathology, University of California, San Francisco, California, USA

Correspondence

Lawren VandeVrede, Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA.
Email: Lawren.VandeVrede@ucsf.edu

Funding information

National Institutes for Health, Grant/Award Numbers: P30AG062422, P01AG019724, U01AG057195, K23AG073514, K23AG059888, K24AG053435, T32AG023481; Rainwater Charity Foundation (L.V.), Alzheimer's Association (L.V.); AlzOut (J.C.R.); Shenandoah Fund (L.V., J.C.R.); John Douglas French Alzheimer's Foundation (J.C.R.)

Abstract

INTRODUCTION: Lewy body disease (LBD) is a common primary or co-pathology in neurodegenerative syndromes. An alpha-synuclein seed amplification assay (α Syn-SAA) is clinically available, but clinical performance, especially lower sensitivity in amygdala-predominant cases, is not well understood.

METHODS: Antemortem CSF from neuropathology-confirmed LBD cases was tested with α Syn-SAA ($N = 56$). Diagnostic performance and clinicopathological correlations were examined.

RESULTS: Similar to prior reports, sensitivity was 100% for diffuse and transitional LBD (9/9), and overall specificity was 96.3% (26/27). Sensitivity was lower in amygdala-predominant (6/14, 42.8%) and brainstem-predominant LBD (1/6, 16.7%), but early spread outside these regions (without meeting criteria for higher stage) was more common in α Syn-SAA-positive cases (6/7, 85.7%) than negative (2/13, 15.4%).

DISCUSSION: In this behavioral neurology cohort, α Syn-SAA had excellent diagnostic performance for cortical LBD. In amygdala- and brainstem-predominant cases, sensitivity was lower, but positivity was associated with anatomical spread, suggesting α Syn-SAA detects early LBD progression in these cohorts.

KEYWORDS

alpha synuclein, cerebrospinal fluid, dementia with Lewy bodies, Lewy body disease, seed amplification assay

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2024 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Highlights

- A cerebrospinal fluid alpha-synuclein assay detects cortical LBD with high sensitivity/specificity.
- Positivity in prodromal stages of LBD was associated with early cortical spread.
- The assay provides precision diagnosis of LBD that could support clinical trials.
- The assay can also identify LBD co-pathology, which may impact treatment responses.

1 | BACKGROUND

Lewy body disease (LBD) is the underlying or contributing neuropathology in many neurodegenerative presentations seen in the behavioral neurology clinic, especially syndromes strongly associated with primary α -synucleinopathies, for example, dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). LBD is also common as a co-pathology in syndromes where the primary pathology is Alzheimer's disease (AD), with some degree of comorbid LBD reported in upwards of 50% of AD cases.¹ Unfortunately, the sensitivity of a clinical diagnosis is relatively low for LBD pathology,^{2,3} suggesting a high proportion of cognitively impaired patients with clinically relevant LBD pathology goes unrecognized.⁴ Inadequate clinical detection is especially prevalent when LBD is present as co-pathology in a patient with high levels of AD neuropathology, and this has been associated with decreased prevalence of core LBD clinical features like hallucinations and fluctuations.^{5,6} Therefore, increased detection is critical both to improve precision diagnosis for primary LBD, which would facilitate clinical trials in syndromes with underlying α -synucleinopathies, and to improve the detection of LBD co-pathology in AD-related syndromes, where it may impact outcomes of disease-modifying therapies.⁷

Recent developments of cerebrospinal fluid (CSF) α -synuclein (α Syn) seed amplification assays (SAAs) have proven to be highly sensitive and specific to the presence of seed-competent α Syn in Parkinson's disease (PD),^{8,9} and autopsy validation studies have shown excellent diagnostic performance for α Syn-SAA detection of cortical LBD, but lower sensitivity in amygdala- and brainstem-predominant LBD,^{10,11} which may represent precursor stages of LBD cortical spread. Interestingly, in patients with isolated rapid eye movement sleep behavior disorder (IRBD), thought to be a prodromal symptom in α Syn-related clinical syndromes, the sensitivity of α Syn-SAA is 90% or higher,^{12,13} further increasing the need to better understand lower sensitivity in amygdala- and brainstem-predominant LBD.

Therefore, we investigated the diagnostic performance and clinicopathological correlations of a clinically available α Syn-SAA (SYNTap Biomarker Test) in CSF from autopsied patients with ante mortem clinical evaluation through a single center's observational studies, with a focus on comparison between clinical and neuropathological characteristics in detected and undetected cases, especially in cases with amygdala- and brainstem-predominant LBD.

2 | METHODS

2.1 | Participant characteristics

This retrospective autopsy study included participants of observational studies seen between 2009 and 2017 at the University of California, San Francisco (UCSF) Memory and Aging Center (MAC). Autopsies were performed by the Neurodegenerative Disease Brain Bank (NDBB) at the UCSF Alzheimer Disease Research Center between 2011 and 2021. All participants provided written informed consent at time of recruitment and underwent a comprehensive clinical research evaluation, including cognitive testing and neurological examination.¹⁴ Studies were approved by the Institutional Review Board at UCSF. A total of $N = 879$ available autopsies were queried, and 28.2% had LBD neuropathology. Of these participants with LBD, $N = 29$ had available ante mortem CSF. To compare the prevalence of clinical features, cases without LBD with ante mortem CSF were chosen to match clinical syndromes ($N = 27$; Table 1 and Table S1). Clinical syndrome was diagnosed based on available data at the time of clinical evaluation by an experienced behavioral neurologist or formal consensus panel following established criteria, updated when necessary to follow contemporary nomenclature (LV).^{6,15-19} All available clinical data were reviewed to determine ante mortem symptoms at the closest time point to CSF collection (NS, SL, DLF).

2.2 | Autopsy assessment

Postmortem brain tissue was processed and analyzed in the NDBB according to previously described standard protocols, including stage of AD neuropathological change (ADNC) and presence of co-pathology.²⁰⁻²⁴ Of note, multiple neuropathological staging systems are available for LBD; here, McKeith et al. criteria were used with the incorporation of "amygdala-predominant" as described in Leverenz et al.^{20,21} In brief, four categories are reported based on the distribution of α Syn immunohistochemical staining: brainstem-predominant (roughly equivalent to Braak stages 1 to 3), transitional-limbic (limbic, roughly equivalent to Braak stage 4), diffuse neocortical (roughly equivalent to Braak stages 5 to 6).²⁵ We also had the category amygdala-predominant, which does not follow the traditional Braak

RESEARCH IN CONTEXT

- 1. Systematic review:** The authors reviewed the literature using traditional sources, for example, PubMed. Accurate detection of Lewy body disease (LBD) neuropathology is urgently needed, and a clinically available alpha-synuclein seed amplification assay (α Syn-SAA) has been validated in recent publications. However, numerous clinicopathological questions remain, especially low sensitivity in amygdala- and brainstem-predominant cases.
- 2. Interpretation:** We found excellent diagnostic performance to detect cortical LBD in this autopsy-confirmed behavioral neurology cohort. We also describe an association between positivity in amygdala- and brainstem-predominance stages and early spread into the cortex, suggesting the α Syn-SAA assay accurately detects LBD, even when co-pathology.
- 3. Future directions:** The diagnostic performance needs to be confirmed in larger and more diverse cohorts, preferably in a real-world clinical setting. Additional contexts of use should be explored, especially prognostic and theragnostic applications, such as the impact of LBD on disease-modifying therapies in AD.

staging system but is a relatively common finding in early-onset AD.²⁶ Following prior convention, cases with cortical LBD in the transitional and diffuse stages were combined for analyses.^{10,11}

2.3 | CSF analysis

After lumbar puncture, CSF was collected by gravity in polypropylene tubes, aliquoted (0.5 mL), and stored at -80°C until use, according to standard protocol. CSF was sent to Amprion's Clinical Laboratory Improvement Amendment/College of American Pathologists (CLIA/CAP) certified laboratory for qualitative α Syn-SAA analysis (SYNTap Biomarker Test), as previously described.^{3,10} Assays were performed by operators blinded to sample identity, and results were returned prior to unblinding.

2.4 | Statistical analysis

Overall diagnostic performance for α Syn-SAA to detect pathological LBD was calculated, including sensitivity and specificity for subgroups of LBD pathology. Statistical comparisons were made both among neuropathological cohorts and between α Syn-SAA status on various demographic features, clinical symptoms, measures of clinical severity, and neuropathologic characteristics using linear or logistic regression as appropriate. Statistical analyses were performed using Stata version 17.0 (StataCorp).

3 | RESULTS**3.1 | Diagnostic performance of α Syn-SAA to detect LBD**

In the entire cohort ($N = 56$), α Syn-SAA was 55.2% sensitive (95% confidence interval [CI] 35.7% to 73.6%) and 96.3% specific (95% CI 81.0% to 99.9%). The total prevalence of LBD pathology in the UCSF NDBB was 28.2%, resulting in an estimated positive predictive value (PPV) of 85.4% (95% CI 45.4% to 97.6%) and an estimated negative predictive value (NPV) of 84.5% (95% CI 78.4% to 89.2%) for autopsy-confirmed LBD pathology of any type (Figure 1). In subgroup analyses, α Syn-SAA had perfect sensitivity to detect diffuse (4/4) and transitional (5/5) LBD and detected α Syn in 3/3 cases where LBD was considered the primary neuropathology. Consistent with prior reports,^{10,11} sensitivity was lower in amygdala-predominant LBD co-pathology (6/14, 42.8%), and sensitivity was lower for brainstem-predominant LBD co-pathology (1/6, 16.7%). One false positive result was present in 27 non-LBD cases (3.7%), in which the primary pathology was AD (the participant also lacked clinical features of DLB). In four participants with a clinical diagnosis of DLB, α Syn-SAA was positive in three cases due to diffuse or transitional LBD. In the α Syn-SAA negative DLB case, the participant had brainstem-predominant LBD, but the primary pathology was TAR DNA-binding protein 43 (TDP-43), type B due to a pathogenic variant of *C9ORF72*.

Parkinsonism (frequently atypical) was a clinical feature in 36 participants, including six participants with progressive supranuclear palsy Richardson's syndrome (PSP-RS) and 11 participants with corticobasal syndrome (CBS). In this mixed/atypical parkinsonism cohort, α Syn-SAA had a 68.8% sensitivity (95% CI 41.3% to 89.0%) and 100% specificity (95% CI 83.2% to 100.0%) to detect underlying LBD. In the cohort of patients with a clinical diagnosis of PSP-RS, α Syn-SAA positively detected LBD in one case caused by diffuse LBD and AD co-pathology (a rare PSP-RS mimic), whereas 5/5 cases were true negatives. Within patients with a clinical diagnosis of CBS, α Syn-SAA was positive in 1/1 case with diffuse LBD co-pathology, 0/1 case with amygdala-predominant LBD, and 1/2 cases with brainstem-predominant LBD, whereas 7/7 cases were true negatives.

3.2 | Comparison of antemortem clinical features

Compared to non-LBD, amygdala-predominant cases were more likely to carry an *APOE* $\epsilon 4$ allele (83% vs 42%, $p < 0.05$), and they also had a higher average stage of AD neuropathological change (ADNC 2.7 ± 0.8 vs 1.5 ± 1.2 , $p < 0.05$), with an overall higher prevalence of AD co-pathology (defined as ADNC intermediate or high; 85% vs 33%, $p < 0.05$). Notably, in amygdala-predominant LBD, the interval between CSF collection and autopsy was over a year longer than all other groups (eg, 4.9 ± 2.9 years vs 3.5 ± 1.4 years for non-LBD, $p < 0.05$), which may decrease sensitivity as LBD pathology can develop in the interim. Diffuse/transitional cases showed lower brain weights when compared to non-LBD cases (1229 ± 145 g vs 1111 ± 135 g). In

TABLE 1 Clinical characteristics. Statistical comparisons were performed with linear or logistic regression as appropriate.

	Total N = 56	Non-LBD N = 27	Diffuse / Transitional N = 9	Amygdala- predominant N = 14	Brainstem- predominant N = 6	αSyn-SAA negative N = 39	αSyn-SAA positive N = 17
Demographics							
Age at onset, y	60 ± 9	59 ± 9	64 ± 10	60 ± 12	59 ± 5	59 ± 9	64 ± 11
Age at death, y	70 ± 9	69 ± 8	75 ± 9	69 ± 12	68 ± 6	68 ± 9	73 ± 9
CSF-autopsy interval, y	3.8 ± 2.1	3.5 ± 1.4	3.2 ± 1.8	4.9 ± 2.9 [†]	3.7 ± 2.9	3.9 ± 2.1	3.5 ± 2.2
Female, No., %	26, 46%	17, 63%	3, 33%	5, 36%	1, 17%	21, 54%	5, 29%
Education, y	17 ± 3	17 ± 2	18 ± 2	17 ± 3	16 ± 3	17 ± 2	18 ± 3
APOE ε4 carrier, No., %	25, 47%	11, 42%	2, 22%	10, 83% [†]	2, 33%	18, 50%	7, 41%
Clinical severity							
MMSE	21.9 ± 6.0	22.5 ± 6.1	21.8 ± 6.7	22.1 ± 5.1	19.4 ± 7.0	22.3 ± 5.8	21.2 ± 6.2
CDR, global	1.0 ± 0.6	0.9 ± 0.6	1.3 ± 0.8	0.9 ± 0.4	1.2 ± 0.7	1.0 ± 0.6	1.1 ± 0.7
CDR, box score	5.6 ± 3.5	5.2 ± 3.3	6.9 ± 4.5	5.1 ± 2.6	6.6 ± 4.8	5.7 ± 3.4	5.5 ± 3.9
CDR+NACC FTLD, global	1.3 ± 0.7	1.2 ± 0.7	1.6 ± 0.7	1.2 ± 0.5	1.4 ± 0.7	1.3 ± 0.7	1.3 ± 0.7
CDR+NACC FTLD, box score	7.5 ± 4.2	6.8 ± 3.7	9.1 ± 5.4	6.8 ± 3.4	9.3 ± 5.5	7.5 ± 4.0	7.6 ± 4.6
Clinical symptoms							
Parkinsonism, No., %	36, 64%	19, 70%	7, 78%	7, 50%	3, 50%	25, 64%	11, 65%
RBD, No., %	9, 16%	5, 19%	2, 22%	1, 7%	1, 17%	5, 13%	4, 24%
Dysautonomia, No., %	5, 10%	4, 17%	1, 11%	0, 0%	0, 0%	4, 11%	1, 6%
Fluctuations, No., %	9, 17%	3, 13%	3, 33%	3, 21%	0, 0%	6, 17%	3, 18%
Anxiety, No., %	20, 36%	8, 30%	5, 55%	6, 43%	1, 17%	13, 33%	7, 41%
Depression, No., %	23, 41%	11, 41%	4, 44%	6, 43%	2, 33%	17, 44%	6, 35%
Hallucinations, No., %	6, 11%	0, 0%	4, 44%	1, 7%	1, 17%	1, 3%*	5, 29%*
Neuropathology							
Brain weight, g	1132 ± 143	1111 ± 135	1229 ± 145 [†]	1114 ± 143	1121 ± 143	1105 ± 142*	1192 ± 129*
ADNC	1.8 ± 1.2	1.5 ± 1.2	2.2 ± 1.2	2.7 ± 0.8 [†]	0.8 ± 0.4	1.7 ± 1.2	2.2 ± 1.1
AD pathology, No., %**	27, 48%	9, 33%	6, 66%	12, 85% [†]	0, 0%	16, 41%	11, 65%
FTLD-tau, No., %	20, 36%	12, 44%	3, 33%	1, 7% [†]	4, 67%	16, 41%	4, 24%
FTLD-TDP, No., %	13, 23%	7, 26%	0, 0%	4, 29%	2, 33%	11, 28%	2, 12%

Abbreviations: LBD, Lewy body disease; CSF, cerebrospinal fluid; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating Scale; NACC, National Alzheimer's Coordinating Center; FTLD, frontotemporal lobar degeneration; RBD, rapid eye movement sleep behavior disorder; ADNC, Alzheimer's disease neuropathological change (0 = none, 1 = low, 2 = intermediate, 3 = high); TDP, TAR DNA-binding protein.

[†]Significantly different from non-LBD ($p < 0.05$).

*Significantly different from each other ($p < 0.05$).

**Presence of AD neuropathology defined as ADNC of intermediate or high

patients with a positive αSyn-SAA compared to negative tests, hallucinations were more common (29% vs 3%, $p < 0.05$) and brain weights were higher (1192 ± 129 g vs 1105 ± 142 g, $p < 0.05$). Otherwise, no difference was seen between LBD subgroups on clinical severity or a range of clinical symptoms (Table 1).

In the amygdala-predominant cohort, αSyn-SAA positivity was associated with an older age at onset (63 ± 14 years vs 58 ± 11 years in the negative αSyn-SAA group, $p < 0.05$) and pathologic spread beyond the amygdala (83.3% vs 25.0%, $p < 0.05$; Figure 2, Table S2), where the burden of LBD was concentrated in the amygdala but

present to a trace degree in other structures (but not enough to change the LBD stage and still not conforming to Braak PD staging).²⁵ Syndromic features of DLB thought to be highly specific for LBD, including visual hallucinations and RBD, were only seen in participants with a positive test but were rare overall ($N = 1$ for each). In the brainstem-predominant cohort, only one case in six was αSyn-SAA positive, but intriguingly this participant reported RBD and had LBD pathology spread to the anterior cingulate cortex, differing from the other five cases that did not show LBD spread beyond the brainstem.

Diagnostic Performance Across Neuropathological Cohorts

Overall Sensitivity: 55.2% Overall Specificity: 96.3% (N = 56)




FIGURE 1 Diagnostic performance of CSF α Syn-SAA by LBD Neuropathological Stage. Color code by diagnostic status at figure bottom. Patients inside brown box were diagnosed with DLB while alive (sensitivity 13.8%, specificity 80%). Arrow highlights patient with brainstem-predominant LBD who also had RBD. See Table S1 for full clinicopathological details.

4 | DISCUSSION

In this retrospective autopsy validation study of clinical syndromes and neuropathological entities commonly encountered in the field of behavioral neurology, we find that a clinically available CSF α Syn-SAA (SYNTap Biomarker Test) had excellent diagnostic performance to detect cortical LBD, including diffuse and transitional stages, with a high degree of specificity in the cohort overall. The sensitivity of α Syn-SAA in subjects with cortical pathology is similar to prior studies, with this assay showing excellent diagnostic performance for the detection of LBD, even in prodromal stages of α Syn with isolated RBD.^{9,10} Comparison across assays should be considered cautiously given differences in diagnostic performance, but, reassuringly, other α Syn-SAAs have similar profiles.^{11,12} One point to note is that CSF collection occurred earlier in the disease course of amygdala-predominant patients (i.e., longer CSF-autopsy interval), which may negatively impact diagnostic performance in this subgroup.

In amygdala- and brainstem-predominant cases, we found comparatively low sensitivity, in line with prior reports,^{10,11} but we found that detection in these groups was associated with early α Syn pathology

spread beyond the initial site of involvement. This finding supports the hypothesis from prior work using this and a related assay that α Syn-SAA may have a threshold of detection dependent on the number of pathogenic seeds in the CSF, which reflects the extent of pathological deposition.^{10,27} Alternatively, as this assay primarily detects pathogenic “seed-competent” α Syn fragments, amygdala-predominant LBD may comprise a heterogeneous profile of α Syn species, with one subgroup (detected by α Syn-SAA) reflecting an early LBD stage transitioning to more diffuse spread.

In this cohort, we found that the DLB clinical syndrome and even highly specific core clinical characteristics (eg, RBD and visual hallucinations) were poorly predictive of underlying LBD, primarily due to low prevalence, whereas clinical symptoms like parkinsonism, dysautonomia, fluctuations, and depression/anxiety were more common overall but non-specific for underlying LBD neuropathology, also consistent with prior reports.² The low sensitivity of clinical criteria is a particular problem in the face of evidence, suggesting that up to 50% of patients with AD may have comorbid LBD and 23% of all patients with cognitive symptoms may have clinically relevant LBD,^{1,4} which may impact the outcome of treatment with newly approved anti-amyloid antibodies.⁷




FIGURE 2 CSF α Syn-SAA positivity is associated with spread in amygdala-predominant LBD. (A) Schematic showing amygdala-predominant LBD concentrated in amygdala (red); it may be confined there, or it may be found to a lesser degree in mesial temporal lobe structures (hippocampus or entorhinal cortex) or substantia nigra (yellow), adapted from Attens et al. (2021).³¹ Immunohistochemical staining for all α Syn species in a representative case shows abundant Lewy bodies and Lewy neurites in the amygdala at low (10 \times , B) and high (40 \times , C) magnification with little LBD in the entorhinal cortex (20 \times , D). Scale bars: 100 μ m (B), 25 μ m (C), and 50 μ m (D).

In the modern era, the field of behavioral neurology is tasked with predicting underlying neuropathology based on patients presenting clinical symptoms, a complex endeavor given the high prevalence of co-pathologies in neurocognitive disorders of age,^{26,28} made somewhat easier by the recent implementation of several tests in the clinic that reliably identify AD neuropathology. However, a reliable, predictive marker for clinically relevant α Syn is of particular importance as LBD is the second most common neurodegenerative pathology to cause dementia.²⁹ The advent of new clinical diagnostic tools for LBD is well timed in an era when precision diagnosis supported by biomarker confirmation is increasingly preferred,³⁰ but appropriate clinical use of a LBD-specific biomarker has yet to be defined for patients with cognitive, behavioral, and/or motor symptoms that may be related to LBD.

Future analyses of the use of α Syn-SAA in clinical contexts likely would benefit from a prospective design. Here, a retrospective analysis limited the degree to which clinical symptoms could be specifically queried, which can impact assessments of prevalence. Our assessment of RBD, for example, relied on participant report, rather than on polysomnography or structured questionnaire, and it is possible that careful ante mortem phenotyping of sleep and autonomic symptoms would yield different results, as RBD was previously reported to strongly correlate with α Syn-SAA positivity.⁹ Prospective design with incorporation of modern structured collection tools could yield different results. Additionally, given the years-long gap between CSF collection and autopsy, sensitivity may be underestimated. The advent of PET biomarkers for α Syn would greatly (and reciprocally) facilitate future validation efforts.

Our study has additional limitations, including small sample size, though it is larger than many autopsy studies and comparable to prior validation efforts, and our cohort benefits from extensive ante mortem phenotyping not typically available in autopsy studies. For all studies validating an in vivo marker to autopsy, any variability in biomarker-to-autopsy interval will impact assessment of diagnostic performance, and here that interval was longer for amygdala-predominant LBD. As this is a research cohort drawn from observational studies, the findings may not generalize to that of a routine clinic population, where co-pathologies may be more common. Additionally, referral bias may also impact prevalence calculations, which should be interpreted cautiously. Findings on diagnostic performance also need replication in an ethnically and racially diverse cohort given the lack of diversity in this dataset (Table S1). Another consideration is that newer LBD diagnostic criteria now include an olfactory-only stage,³¹ which for practical reasons was not applied retroactively in this study. Future work with α Syn-SAA may utilize a quantitative assay to reflect subtler prodromal neurochemical abnormalities.

In conclusion, we report excellent diagnostic performance for a clinically available α Syn-SAA to detect cortical LBD pathology, validated against autopsy, in a behavioral neurology cohort not enriched for DLB diagnoses. Differing diagnostic performance in amygdala- and brainstem-predominant cohorts may be affected by the degree of spread from the initial site of involvement, with α Syn-SAA more likely to detect cases with early cortical spread.

ACKNOWLEDGMENTS

The authors thank the patients and their families who participated in this research, as well as staff and investigators at the University of California, San Francisco (UCSF) Memory and Aging Center (MAC). This publication was made possible by grant number P01AG019724 and P30AG062422 from the National Institute on Aging. Funding was provided by National Institutes for Health: P30AG062422, P01AG019724, U01AG057195, K23AG073514 (LV), K23AG059888 (JCR), K24AG053435 (LTG), T32AG023481 (DLF, NS, SL), as well as the Rainwater Charity Foundation, the Alzheimer's Association (L.V.), AlzOut (J.C.R.), Shenandoah Fund (L.V., J.C.R.), and the John Douglas French Alzheimer's Foundation (J.C.R.). The funders had no role in study design or analysis.

CONFLICT OF INTEREST STATEMENT

L.V. is a site principal investigator (PI) for Biogen-sponsored clinical trials in AD. P.A.L. reported grants from the Alzheimer's Association Part the Cloud program; serving as PI for trials sponsored by Woolsey Pharmaceuticals, Transposon, Alector, and AbbVie. J.C.R. is a site PI for clinical trials sponsored by Eli Lilly and Eisai. A.M.S. has provided consultation to Alector, Lilly/Prevail, Passage Bio, and Takeda. J.L. and L.C.M. are employees of Amprion, Inc. A.L.B. reported grants from Rainwater Charitable Foundation during the conduct of the study and stocks/options from Alector, Arvinas, Arkuda, Truebinding, and AZTherapies; personal fees from the AIDS Clinical Trials Group, Boehringer Ingelheim, GSK, Denali Therapeutics, Oligomerix, Merck, Roche, Transposon, Wave, Oscotec, and Alzprotect; and grants from Biogen, Eisai, Regeneron, Bluefield Project, the Alzheimer's Association, and CurePSP. Other authors have no relevant disclosures. Author disclosures are available in the [supporting information](#)

CONSENT STATEMENT

All participants provided written informed consent at time of recruitment.

REFERENCES

- Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. *Brain Pathol.* 2000;10(3):378-384. doi:10.1111/j.1750-3639.2000.tb00269.x
- Nelson PT, Jicha GA, Kryscio RJ, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. *J Neurol.* 2010;257(3):359-366. doi:10.1007/s00415-009-5324-y
- Middleton JS, Hovren HL, Kha N, et al. Seed amplification assay results illustrate discrepancy in Parkinson's disease clinical diagnostic accuracy and error rates. *J Neurol.* Published online August 17, 2023. doi:10.1007/s00415-023-11810-2
- Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. *Nat Med.* 2023;29(8):1964-1970. doi:10.1038/s41591-023-02449-7
- McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology.* 2005;65(12):1863-1872. doi:10.1212/01.wnl.0000187889.17253.b1
- McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology.* 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058
- Vandevrede L, La Joie R, Horiki S, et al. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab. *Acta Neuropathol.* 2023;146(5):777-781. doi:10.1007/s00401-023-02631-8
- Concha-Marambio L, Pritzkow S, Shahawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. *Nat Protoc.* 2023;18(4):1179-1196. doi:10.1038/s41596-022-00787-3
- Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet Neurol.* 2023;22(5):407-417. doi:10.1016/S1474-4422(23)00109-6
- Arnold MR, Coughlin DG, Brumbach BH, et al. alpha-Synuclein Seed Amplification in CSF and brain from patients with different brain distributions of pathological alpha-Synuclein in the context of Co-Pathology and Non-LBD diagnoses. *Ann Neurol.* 2022;92(4):650-662. doi:10.1002/ana.26453
- Hall S, Orrù CD, Serrano GE, et al. Performance of alphaSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. *Acta Neuropathol Commun.* 2022;10(1):90. doi:10.1186/s40478-022-01388-7
- Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. *Lancet Neurol.* 2021;20(3):203-212. doi:10.1016/S1474-4422(20)30449-X
- Concha-Marambio L, Weber S, Farris CM, et al. Accurate detection of alpha-Synuclein seeds in Cerebrospinal Fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson's disease in the DeNovo Parkinson (DeNoPa) Cohort. *Mov Disord.* 2023;38(4):567-578. doi:10.1002/mds.29329
- Perry DC, Brown JA, Possin KL, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. *Brain.* 2017;140(12):3329-3345. doi:10.1093/brain/awx254
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology.* 1984;34(7):939-944. doi:10.1212/wnl.34.7.939
- Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology.* 2011;76(11):1006-1014. doi:10.1212/WNL.Ob013e31821103e6
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain.* 2011;134(9):2456-2477. doi:10.1093/brain/awr179. Pt.
- Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology.* 2013;80(5):496-503. doi:10.1212/WNL.Ob013e31827f0fd1
- Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. *Mov Disord.* 2017;32(6):853-864. doi:10.1002/mds.26987
- McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. *J Alzheimers Dis.* 2006;9(3):417-423. doi:10.3233/jad-2006-9s347. Suppl.
- Leverenz JB, Hamilton R, Tsuang DW, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. *Brain Pathol.* 2008;18(2):220-224. doi:10.1111/j.1750-3639.2007.00117.x
- Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol.* 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3

23. Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. *Acta Neuropathol.* 2009;117(1):15-18. doi:10.1007/s00401-008-0460-5
24. Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain.* 2019;142(6):1503-1527. doi:10.1093/brain/awz099
25. Braak H, Del Tredici K, Rüb U, de Vos RAI, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging.* 2003;24(2):197-211. doi:10.1016/s0197-4580(02)00065-9
26. Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. *Brain.* 2021;144(7):2186-2198. doi:10.1093/brain/awab099
27. Bentivenga GM, Mammana A, Baiardi S, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. *Acta Neuropathol.* 2024;147(1):18. doi:10.1007/s00401-023-02663-0
28. Fischer DL, Seeley WW. A precision medicine approach to Dementia Care: syndrome, Etiology, and Copathology. *Pract Neurol (Fort Wash Pa).* 2023;2023:17-22.
29. Yamada M, Komatsu J, Nakamura K, et al. Diagnostic Criteria for Dementia with Lewy Bodies: updates and Future Directions. *J Mov Disord.* 2020;13(1):1-10. doi:10.14802/jmd.19052
30. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
31. Attems J, Toledo JB, Walker L, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. *Acta Neuropathol.* 2021;141(2):159-172. doi:10.1007/s00401-020-02255-2

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Samudra N, Fischer DL, Lenio S, et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. *Alzheimer's Dement.* 2024;20:3334-3341. <https://doi.org/10.1002/alz.13799>